Premium – Endpoints News

SUBSCRIBE

Gene therapy R&D deals turn red hot as Big Pharma steps up to play

Last week

Biopharma BD teams are speeding into the fast lane — cash in hand — as dealmaking continues to heat up in Q1 offensive

Last month

The top 50 biotechs by market cap — and what their CEOs’ compensation deals tell us about biopharma

Last month

The BCMA frenzy: Tracking the 37 drugs around the world racing to overtake bluebird bio and Celgene

Last month

Top 5 Chinese players: What does Everest's landmark deal with Immunomedics say about the flurry of in-licensing to China?

Last month

Going gangbusters: The top 20 biotech platform deals by upfront cash

2 months ago

Another player in the gene therapy field is gunning for the Duchenne MD crown — and here’s what they're betting on

2 months ago

The top 20 preclinical biotech deals ranked by cash upfront reveals 3 big players — and some major league stinkers

2 months ago

Top 20 cancer drug deals: AstraZeneca just changed the global landscape for dealmaking in oncology

2 months ago

The top 10 Alzheimer's deals tell us a lot about a big change of direction for a disaster-prone field

3 months ago

Team building. Pipeline revamp. Forward thrust. What does a decade of deals at Gilead tell us about Daniel O’Day’s first M&A moves?

3 months ago

After a slate of small, tack-on acquisitions, is Merck ready to pull the trigger on a big M&A deal?

3 months ago

By the numbers: Top M&A deals, VC investments and pacts point to a growing hunger for gene therapy deals

3 months ago

The $100M biotech club: Who's in, and what’s it take to join the top-performing group of biopharmas?

4 months ago

The high rollers: The top 20 blockbuster biopharma deals of the past decade

4 months ago

Top 20 biotech deals: 2019 dealmaking gets off to a roaring start, building on a record amount for '18

4 months ago

AstraZeneca CEO Soriot is overseeing a top exec team overhaul in move to integrate MedImmune in a sweeping restructuring

4 months ago

Path to the top: What kind of experience does it take to get tapped for the helm of a biotech?

4 months ago

By the numbers for 2018: The top 100 venture players in biotech — and who's been paying the piper in cancer R&D?

4 months ago

Scoop: GSK’s venture team at SR One in talks to spin off from its big pharma founder, now under new R&D management

4 months ago

Celgene's top 20 upfront hits: Just how generous was Celgene in dealmaking? Let's review the records

5 months ago

So what did we learn from JPMorgan week? Buckle up, it’s going to be a bumpy ride

5 months ago

‘It’s us against the world’: And George Yancopoulos wants you to know they are beating the world — big time

5 months ago

The 2018 breakdown on a chart-topping set of new drug approvals — and the 5 big things we learned from it

5 months ago

12 Next page Last page